Fosamax Lawyer

Aug 9, 2012 by jayschmale49

Problems with Fosamax

When Fosamax (alendronate) was first introduced to the U.S. market place in 1995, it was hailed as a miracle treatment for the 40 million Americans who either already have osteoporosis or are at threat for developing the disease. The class of drugs to which Fosamax belongs, bisphosphonates, work by slowing the body’s natural bone breakdown approach. By inhibiting bone turnover, bisphosphonates can aid keep the skeletal method robust. In some cases, nonetheless, they can start to interfere with bone metabolism and truly result in bones to weaken.

This might be why some patients taking Fosamax for osteoporosis or Paget’s disease experience bone troubles. 1 of these is osteonecrosis (literally “bone death”), a condition that interrupts the blood provide to bone tissue, causing the tissue to die.

For information on Fosamax femur risk go to